期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌雌激素受体、孕激素受体和C—erbB-2在不同新辅助化疗前后的变化 被引量：5

Changes of estrogen receptor, progesterone receptor and C-erbB-2 expressions in different scheme pre- and post-neoadjuvant chemotherapies for breast cancer
原文传递
导出
摘要 新辅助化疗在局部晚期乳腺癌的治疗中已被越来越广泛的应用。近年来研究表明，不同新辅助化疗前后肿瘤组织中雌激素受体（ER）、孕激素受体（PR）和人类表皮生长因子受体-2（C-erbB-2）的表达可能发生变化。在同时含有蒽环类及紫衫类化疗药物的新辅助化疗方案中改变较为明显，而在以蒽环类化疗药物为主的方案中无明显变化。 Neoadjuvant chemotherapy is widely used in the therapy of locally advanced breast cancer. In the recent studies, the expressions of ER, PR and C-erbB-2 in tumor may change in different scheme preand post-neoadjuvant chemotherapies for breast cancer. It is obviously changed in the neoadjuvant chemotherapy scheme of anthracyclines and paclitaxeL/docetaxel, but hardly changed in anthracycline-based neoadjuvant chemotherapy scheme.
作者 史蓬亮 张乃千 张国强
机构地区 哈尔滨医科大学附属第三医院乳腺外科
出处 《国际肿瘤学杂志》 CAS 2013年第2期117-119,共3页 Journal of International Oncology
关键词 乳腺肿瘤 新辅助化疗 受体 雌激素 受体 孕酮 受体 ERBB-2 Breast neoplasms Neoadjuvant chemotherapy Receptors, estrogen Receptors, proges-terone Receptor, erbB-2
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1Lo SS,Wang HC,Shyr YM. Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy[J].Journal of Surgical Oncology,1994,(02):94-96.
  • 2Faneyte IF,Schrama JG,Peterse JL. Breast cancer response to neoadjuvant chemotherapy:predictive markers and relation with outcome[J].British Journal of Cancer,2003,(03):406-412.
  • 3Pedrini JL,Francalacci Savaris R,Casales Schorr M. The effect of neoadjuvant chemotherapy on hormone receptor status,HER2/neu and prolactin in breast cancer[J].Tumori,2011,(06):704-710.
  • 4Lee SH,Chung MA,Quddus MR. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer[J].American Journal of Surgery,2003,(04):348-350.
  • 5Kasami M,Uematsu T,Honda M. Comparison of estrogen receptor,progesterone receptor and Her-2 status in breast cancer preand post-neoadjuvant chemotherapy[J].Breast,2008,(05):523-527.
  • 6Adams AL,Eltoum I,Krontiras H. The effect of neoadjuvant chemotherapy on histologic grade,hormone receptor status,and HER2/neu status in breast carcinoma[J].BREAST JOURNAL,2008,(02):141-146.
  • 7Piper GL,Patel NA,Patel JA. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status[J].American Surgeon,2004,(12):1103-1106.
  • 8Pachnicki JP,Czeczko NG,Tuon F. Immunohistochemical evaluation of estrogen and progesterone receptors of pre-and post-neoadjuvant chemotherapy for breast cancer[J].Rev Col Bras Cir,2012,(02):86-92.
  • 9Kinsella MD,Nassar A,Siddiqui MT. Estrogen receptor (ER),progesterone receptor (PR),and HER2 expression pre-and post-neoadjuvant chemotherapy in primary breast carcinoma:a single institutional experience[J].Int J Clin Exp Pathol,2012,(06):530-536.
  • 10Connor CS,Tawfik OW,Joyce AJ. A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens[J].American Journal of Surgery,2002,(04):322-324.

同被引文献38

  • 1潘一红,陶俊贞,吕荣伟,金芙蓉,林慧敏,周丹红,陶德友.吉西他滨联合卡铂在复发性上皮性卵巢癌治疗中的应用[J].上海交通大学学报（医学版）,2011,31(4):481-483. 被引量：6
  • 2董晖.新辅助化疗或手术治疗ⅢC或Ⅳ期卵巢癌患者[J].中国老年学杂志,2015,35(1):230-231. 被引量：8
  • 3Gluz O, Liedtke C, Gottschalk N, et al. Triple negative breast cancer current status and future directions [ J]. Ann Oncol, 2009, 20 : 1913-1927.
  • 4Taucher S, Ruads M, Gnant M, et al. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy [ J ] . Endocr Relat Cancer, 2003, 10:91-96.
  • 5Frassoldati A, Adami F, Banzi C, et al. Changes of biological features in breast cancer ceils determined by primary chemother- apy[J]. Breast Cancer Treat, 1997, 44 : 185-192.
  • 6Piper GL, Patel NA, Patel JA, et al. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preop- erative tumor marker status [ J ] . Am Surg, 2004, 70: 1103-1106.
  • 7Eifel P, Axelson JA, Costa J, et al. National Institues of Health Consensus Development Conference Statement adjuvant therapy for breast cancer[J]. J Natl Cancer Inst, 2001, 93:979-989.
  • 8Glynn RW, Miller N, Whelan MC, et al.Topoisomerase 2 alpha and the case for individualized breast cancer therapy [J].Ann Surg Oncol,2010, 17(5):1392-1397.
  • 9Fan L,Strasser-Weippl K,Li JJ,et al.Breast cancer in China[J].Lancet Oncol,2014(7):279-289.
  • 10Buchholz TA,Hunt KK,Whitman GJ,et al.Neoadjuvant chemotherapy for breast carcinoma:multidisciplinary considerations of benefits and risks[J].Cancer,2003(6):1150-1160.

引证文献5

二级引证文献21

国际肿瘤学杂志
2013年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部